Stay updated on GSK2586881 in Acute Lung Injury: Clinical Trial

Sign up to get notified when there's something new on the GSK2586881 in Acute Lung Injury: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the GSK2586881 in Acute Lung Injury: Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the safety, tolerability, pharmacokinetics, and pharmacodynamics investigation of GSK2586881 in patients with Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) in a phase IIa study.
    Difference
    0.1%
    Check dated 2024-06-06T14:33:08.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying the inclusion and exclusion criteria for participants. This change provides more specific information about the health conditions and prior treatments required for participation in the study.
    Difference
    39%
    Check dated 2024-05-22T20:33:36.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:52:46.000Z thumbnail image

Stay in the know with updates to GSK2586881 in Acute Lung Injury: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the GSK2586881 in Acute Lung Injury: Clinical Trial page.